Clinical Trial for PGRN Mutation Carriers

FORUM Pharmaceuticals announces dosing of the first patient in a clinical trial to evaluate FORUM’s investigational therapy FRM-0334, which is targeting PGRN mutations. For more information, read the press release. To learn more about the clinical trial, visit

Stay Informed


Sign up now and stay on top of the latest with our newsletter, event alerts, and more…